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Open access under CC BY license.Drug resistance in parasitic nematodes is an increasing
problemworldwide, with resistance reported to all three
commonly used classes of anthelmintics. Most studies
to date have sought to correlate the resistant phenotype
with genotypic changes in putative target molecules.
Although this approach has identified mutations in sev-
eral relevant genes, resistance might result from a com-
plex interaction of different factors. Here we propose an
alternative mechanism underlying the development of
drug resistance based on functional differences inmicro-
RNA activity in resistant parasites. microRNAs play an
important role in resistance to chemotherapeutic agents
in many tumour cells and here we discuss whether they
might also be involved in anthelmintic resistance in
parasitic nematodes.
The problem of drug resistance in parasitic nematodes
Parasitic nematodes of humans and animals remain a
major problem in many areas of the world. Control of these
parasites relies almost exclusively on the use of chemother-
apeutic agents, of which three classes are in common use.
These are the tetrahydropyrimidines/imidazothiazoles
(e.g. pyrantel, levamisole), the benzimidazoles (e.g. fenben-
dazole) and the macrocyclic lactones (e.g. ivermectin, mox-
idectin). Whereas most drugs retain efficacy against
human parasitic nematodes, there are indications that
resistance to ivermectin might be developing in the filarial
nematode Onchocerca volvulus [1]. By contrast, the pro-
blem of drug resistance in veterinary nematodes is wide-
spread, particularly in parasites of sheep, goats and horses
[2] and, more recently, cattle [3]. For sheep parasites such
as Teladorsagia circumcincta and Haemonchus contortus,
resistance has been reported to all three classes of drug
and, indeed, triple-resistant parasites exist in parts of the
world, including Scotland [4]. As well as causing consider-
able economic loss (an estimated £84 million per annum to
the sheep industry in the UK [5]), these pathogens cause
significant welfare problems in infected animals. In the
short term, the availability of novel anthelmintics, such as
the amino-acetonitrile derivative (AAD) [6], monepantel,
marketed as Zolvix, offer temporary relief. Yet, by analogy
with how quickly resistance has developed to the current
compounds, it is probably simply a matter of time before
the efficacy of novel compounds is compromised.
Understanding themode of action of anthelmintics and
the mechanisms of resistance is important in terms ofCorresponding author: Devaney, E. (e.devaney@vet.gla.ac.uk)
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type.Much of our knowledge of mechanisms of drug action
and the likely genes involved in resistance comes from
studies on Caenorhabditis elegans [7], where the relative
ease of generating resistant mutants and identifying
mutations has facilitated such studies. This has beenmost
clearly demonstrated for the b-tubulin gene ben-1, in
which mutations conferred resistance to benzimidazole
(BZ) compounds in C. elegans [8]. In H. contortus,
mutations in the b-tubulin isotype 1 gene (Hc-iso-1) are
also associated with BZ resistance. Transformation of BZ-
resistant C. elegans with the wild-type Hc-iso-1 allele
restores sensitivity to BZ compounds, whereas transform-
ation with themutantHc-iso-1 gene had no such effect [9].
These results helped establish that b-tubulin isotype-1
mutations are a major determinant of BZ resistance in
parasitic nematodes. Confirming a role for specific gene
mutations in resistance to other anthelmintics has, how-
ever, proven more difficult. For example, studies in C.
eleganshave indicated that resistance to ivermectinmight
be polygenic and that mutations at any one contributing
locus may be insufficient for a fully resistant phenotype
[10]. It has been suggested that a similar scenario might
exist in parasitic nematodes [11]. The situation is con-
founded by the significant genetic polymorphism of para-
site populations, particularly for trichostrongylid species
[12],making it difficult to conclude that resistance is due to
a particular polymorphism, or whether other linked
mutations might be responsible.
Recent studies on possible mechanisms of drug resist-
ance in parasitic nematodes have identified mutations
within the coding regions or the promoters of candidate
genes first identified in C. elegans ([11,13–15]). Neverthe-
less, by analogy with other eukaryotes, drug resistance in
nematodes could result from a range of different mechan-
isms in addition to functional mutations in specific genes.
These include altered levels of expression of target or non-
target genes, such as drug transporters or detoxification
enzymes. Changes in the expression of such genes could
arise via a number of different processes such as epigenetic
modifications in chromatin or by a variety of transcrip-
tional or post-transcriptional mechanisms, including
trans-splicing and capping [16]. In tumour cells, one
specific type of post-transcriptional regulation, the altera-
tion of microRNA (miRNA) expression or activity, is
increasingly implicated in drug resistance. In this article
we discuss whether miRNAs are involved in drug resist-
ance in parasitic nematodes.oi:10.1016/j.pt.2010.05.003 Trends in Parasitology 26 (2010) 428–433
Box 1. Biogenesis of miRNAs
miRNAs are transcribed as hairpin precursors, which are sequentially
processed by the RNase III enzymes Drosha and Dicer to imperfectly
paired double-stranded intermediates. One strand of the duplex is
then selectively assembled into a cytoplasmic protein complex,
known as an RNA-induced silencing complex (RISC). Protein coding
mRNAs which contain complementary sequences to the miRNA
(usually in their 30-UTR) are bound by this complex, most often
resulting in translational repression in animals. An example of C.
elegans miR-1 processing is presented on the RHS of the diagram,
with the mature miRNA sequence shown in bold (Figure I).
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Figure I.
Opinion Trends in Parasitology Vol.26 No.9miRNAs
miRNAs are one of a family of endogenous small non-
coding RNAs, including small interfering RNAs (siRNAs)
and piwi-interacting RNAs (piRNAs), that have been
identified in a diverse range of organisms [17]. They were
first identified in C. elegans as key components of the
heterochronic pathway, the mechanism by which develop-
mental timing is regulated in the worm [18,19]. miRNAs
are the focus of intense interest given their important roles
in the control of gene expression in many biological and
pathological processes, such as cell and organ develop-
ment, differentiation and homeostasis, tumour suppres-
sion and stem cell regulation [20]. The biogenesis of
miRNAs (Box 1) and the mechanisms by which they exert
their regulatory function are increasingly understood [21].
miRNAs regulate the expression of target genes at the
post-transcriptional level by base pairing with defined
sites often, but not exclusively, located in the 30-UTR of
target genes. In animal cells, specific miRNAs have beenshown to repress translation, whereas others appear to act
by inducing degradation of the target mRNA. Since their
discovery in C. elegans, miRNAs have been identified in a
diverse range of plants and animals and appear to be
abundant in most genomes; the current version (release
15) of miRBase (http://www.mirbase.org/) identifies 940
miRNAs in humans and 175 in C. elegans. In addition,
up to one third of all humanmRNAs might be regulated by
miRNAs [22]. Now that genome sequence data are avail-
able for several species of parasitic nematode [23], it is
possible to identify miRNAs in parasitic species and to
investigate their roles in the biology of parasites. For
example, a number of important miRNAs including let-7
and lin-4 have been identified in theB.malayi genome [24].
miRNAs and drug resistance in tumour cells
miRNAs have been the focus of much interest in tumour
cell biology because they appear to play a role in the
initiation and progress of some cancers and indeed are429
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Figure 1. Potential mechanisms for miRNA involvement in drug resistance. (a) In
human MCF-7 breast cancer cells, miR-451 negatively regulates translation of the
P-glycoprotein gene mdr-1, via a complementary miR-451 site in the 30-UTR of
mdr-1. In MCF-7 cells resistant to doxorubicin (MCF-7/DOX), decreased levels of
miR-451 result in an increased level of MDR-1 protein with resultant DOX
resistance [28]. (b) In C. elegans, miR-1 negatively regulates the unc-29 nAChR
subunit via three complementary sites in the unc-29 30UTR. In mir-1 null mutants,
UNC-29 protein level is increased, which alters nAChR composition, leading to a
decreased sensitivity to levamisole [37].
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suppressors [25]. In addition, many tumour cells express
an altered profile of miRNAs, which might have diagnostic
and/or prognostic potential [26]. Furthermore, expression
profiling of drug-sensitive and drug-resistant tumour cell
lines has suggested a role for miRNAs in the development
of drug resistance [27]. For example, in the breast cancer
cell line MCF-7, doxyrubicin resistance appears to be
associated with significant changes in the levels of specific
miRNAs [28]. These cells express very high levels of P-
glycoprotein (encoded by the mdr-1 gene), an important
mechanism of drug efflux. The 30-UTR of the mdr-1 gene
contains a binding site for miR-451, which negatively
regulates mdr-1 expression (Figure 1(a)). It was shown
that transfection of doxyrubicin-resistant cells with this
miRNA resulted in decreased levels of P-glycoprotein and a
2.5-fold increase in sensitivity to doxyrubicin.
A number of recent studies have further demonstrated
that drug metabolising enzymes and transporters can be
post-transcriptionally regulated by miRNAs and, impor-
tantly, that changes in expression of many miRNAs are
induced by drug treatment [29]. For example, miR-328 is
downregulated ten-fold in xenograft tumours following
gemcitabine treatment [30]. miR-328 is involved in the
negative regulation of the ABCG2 efflux transporter [31]
and therefore downregulation of miR-328 results in over-
expression of the transporter and multidrug resistance
[30].
As well as altered expression of miRNAs leading to drug
resistance, deletions or mutations within the binding tar-
gets of miRNAs can affect miRNA function. A single
nucleotide polymorphism (SNP) near the binding site of
miR-24 in the 30-UTR of the human dihyrofolate reductase
(DHFR) gene prevents repression by miR-24, resulting in
overexpression of DHFR and resistance to methotrexate430[32]. Indeed mutations within 30-UTR binding sites occur
at a higher level than SNPs in miRNA sequences them-
selves [33], probably because miRNAs have multiple tar-
gets, and therefore miRNA mutation is likely to lead to
more serious consequences. In a different system, several
drug resistant cell lines that overexpress ABCG2 were
shown to contain truncated 30-UTRs. The deleted region
contains a binding site for miR-519c, and the absence of
this binding site in resistant cells leads to overexpression of
ABCG2 and drug resistance [34]. The accumulating data
on miRNA and mRNA expression and drug resistance in
cancer cells are now being integrated to predict responses
to drugs and improve treatment efficiency, an area referred
to as ‘miRNA pharmacogenomics’ [35].
It is possible that a link between miRNAs and drug
resistance is more likely to occur in cancer cells, as the
cancerous state can itself be due to miRNAmis-expression.
However, the study of miRNAs in cancer has clearly estab-
lished that miRNA-mediated alterations in levels of drug
targets, drug transporters, metabolic enzymes or cell apop-
tosis proteins can lead to drug resistance. Altered gene
expression associated with drug resistance in other sys-
tems indicates that examination of miRNA activity and 30-
UTR interactions in parasitic nematodes is warranted to
improve our understanding of drug resistance mechan-
isms.
Could miRNAs have a role in drug resistance in
nematodes?
The study of miRNAs and their functions in parasitic
nematodes is in its infancy, although much is known about
specific miRNAs in C. elegans [36]. Recent work on this
nematode indicates that miRNAs might play a role in drug
resistance, and indicates that this area is ripe for investi-
gation in parasitic nematodes. In C. elegans, miR-1 nega-
tively regulates the expression of two nicotinic
acetylcholine receptor (nAChR) subunits, unc-29 and
unc-63 [37]. Intriguingly, in mir-1 mutants the expression
of both UNC-29 and UNC-63 subunits is increased, and
this corresponds with decreased muscle sensitivity to
acetylcholine and levamisole (Figure 1(b)). It is perhaps
surprising that an increased level of particular AChR
subunits leads to an altered response to levamisole. Never-
theless, it was speculated that altering the subunit com-
position of the AChR could affect receptor biogenesis or
function and that miRNAs can alter the composition and
activity of other heteromultimeric receptors [37]. These
findings are consistent with changes in kinetics and affi-
nity of mammalian nAChRs that follow changes in subunit
composition [38] and are supported by studies on the
Ascaris suum nAChR which highlighted the importance
of subunit composition for drug sensitivity [39].
Interestingly, in a very different approach using immu-
noprecipitation to isolate miRNA-target complexes in C.
elegans during development, mRNAs encoding ion chan-
nels and receptors were particularly enriched in the data
set [36]. Since these types of proteins are well represented
among known drug targets in nematodes, miRNAs might
well be involved in altering their expression and activity.
Recently, two studies in parasitic nematode species
reported alterations in expression levels of receptors and
Box 2. miRNA modulation
Strategies to modulate miRNA levels in cells and organisms have
been developed both to investigate miRNA function experimentally
and for potential therapeutic application. Although genetic mutant
analysis is most reliably informative for functional miRNA studies,
generating mutants is time consuming and not possible with
parasitic nematodes. miRNA levels, unlike protein-coding mRNAs,
cannot be knocked-down using RNAi. However, miRNA function has
been investigated by disruption using chemically engineered
oligonucleotides as competitive inhibitors. These anneal to the
mature RISC-bound miRNA by anti-sense complementarity and
compete for binding to the natural mRNA target. Repression is
therefore removed and target mRNAs become available for transla-
tion. Inhibitory oligonucleotides have been designed bearing
various distinct modifications, such as 20-O-methyl oligonucleotides
(known as antagomirs) [50] or locked nucleic acid (LNA) oligonu-
cleotides [51]. These modifications result in enhanced binding
affinity for target sequences and prevent degradation of the
oligonucleotide by RISC or other cellular ribonucleases. Antisense
oligonucleotides have been used successfully in cultured cells
[52,53], Drosophila embryos [54], C. elegans [55], mouse [50] and
in non-human primates [56]. Multiple miRNAs can be disrupted
simultaneously using mixes of inhibitory oligonucleotides. To
ensure that effects are due only to miRNA inhibition, experiments
should be controlled using antisense oligonucleotides with
scrambled or mis-matched sequences.
In cultured cells, delivery of antisense oligonucleotides is usually
accomplished by lipid transfection or electroporation, whereas
micro-injection is used for Drosophila and C. elegans. In C. elegans
this is currently performed by injection of early larval stage worms
(a technically difficult process), with the effect determined in the
injected animal itself [55]. Techniques to allow inheritance of the
inhibitory oligonucleotides have been developed recently [57].
Uptake of a fluorescently-labelled inhibitory oligonucleotide by
soaking larvae of the filarial nematode Brugia pahangi (Devaney, E.,
and Britton, C., unpublished data) indicates that the approaches
described above for other organisms could be adapted for the study
of parasitic nematode miRNAs.
An alternative to introducing antisense oligonucleotide is high
level expression of transgenes carrying multiple sequences com-
plementary to the miRNA (‘miRNA sponges’) [58]. Here partial
complementarity is used so that sequences are not cleaved;
however, this may result in multiple miRNAs being targeted.
Although more time-consuming, delivery or uptake are not issues
with this approach and it has recently been adapted to provide
tissue-specific and temporal control over miRNA disruption in
Drosophila [59]. Transgenic miRNA inhibition is not currently
applicable to parasitic nematodes but could be adapted for use in
C. elegans. miRNA function can also be investigated by upregulat-
ing their expression, accomplished either by transgenically over-
expressing the miRNA, as performed in cultured cells [60] and C.
elegans [61], or by introducing synthetic miRNAs (miRNA mimics).
In overexpression studies, an opposing effect on target mRNA or
protein level to that produced by inhibition would provide strong
evidence of a true target.
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treatment, changes in transcript levels of the nAChR genes
unc-29, unc-38 and unc-63were found in isolates of the dog
hookworm Ancylostoma caninum [40]. In this case a highly
resistant isolate showed diminished expression of the
three receptor subunit genes compared to an isolate with
a low level of pyrantel resistance. Whether the lower
transcript level of any of these three genes corresponds
with an increase in regulatory miRNA expression or
activity has not been examined, but would be of great
interest. Similarly, isolates of H. contortus resistant to
ivermectin were found to have lowered expression of a
novel ligand-gated ion channel gene (Hc-GGR3) [41]. Inter-
estingly, a SNP was identified in the Hc-GGR3 30-UTR of
resistant worms. It was proposed that this polymorphism
might be associated with resistance, although functional
analysis is required to test this. Given the high degree of
conservation of some miRNA sequences across species,
including the miR-1 sequence, C. elegans presents a suit-
able model system in which to functionally test potential
miRNA-30-UTR interactions, which cannot readily be
examined directly in parasitic species.
As well as changes in expression levels of potential drug
targets, alterations in the expression of drug transporters
have been reported in parasitic nematodes following
anthelmintic treatment. This might be analogous to the
changes in transporter levels in tumour cells exposed to
drugs, as discussed previously. In H. contortus and O.
volvulus, treatment with ivermectin results in a reduction
in allele frequency and overexpression of P-glycoprotein
and other ABC transporter genes [42]. Similarly, two
independent isolates of H. contortus that were selected
for BZ resistance show an elevated frequency of the same
P-glycoprotein allele [14]. Although different drug classes
can interact with different ABC transporters, these find-
ings indicate that the mechanism underlying this allele
selection might be the same and have implications for the
development of resistance to new drug classes. A recent
study in C. elegans also found that exposure to increasing
concentrations of ivermectin resulted in increased expres-
sion of several P-glycoprotein and ABC transporter genes
[43]. It would obviously be interesting to compare the 30-
UTR region of P-glycoprotein genes from susceptible and
resistant nematodes for regulation by miRNAs.
Future perspectives
Herein the possibility that changes in gene expression
levels associated with drug resistance in parasitic nema-
todes are mediated by miRNAs has been discussed. This
might be a mechanism of altering drug efficacy; given the
link between miRNAs and drug responses in cancer cells,
this area is ripe for detailed investigation. With the num-
ber of genome sequencing projects underway, miRNAs
present in parasitic nematodes can be identified using both
in silico approaches [44] (for example by combining BLAST
[45] and RNAfold [46] analysis to search for homologues of
known miRNAs), and small RNA sequencing [24]. Poten-
tial target mRNAs can be identified using available bioin-
formatics programmes such as MiRanda [47] and PicTar
[48], combined with immunoprecipitation of mRNAs in
RISC complexes and sequencing [49]. A number of poten-tial target mRNAs relevant to drug resistance in parasitic
nematodes have been discussed above; bioinformatic and
biochemical approaches can be used to determine whether
these are likely to be real targets of miRNA regulation. A
potential interaction between amiRNAand the 30-UTR of a
target gene from a parasitic nematode could then be ver-
ified using C. elegans as a heterologous expression system.
Currently, the potential correlation between antihel-
mintic resistance and changes in particular gene
sequence or expression level has been limited to the
study of a small number of candidate genes. Examining
and comparing miRNA levels, as well as mRNA expres-
sion in drug resistant and susceptible isolates, through431
Opinion Trends in Parasitology Vol.26 No.9the use of microarrays will produce a global picture of
changes that might correlate with drug resistance. In
addition, miRNA inhibitors and mimics (Box 2) are
available and can be used to examine the upregulation
or downregulation of miRNAs and their potential mRNA
targets. Could these miRNA inhibitors or mimics be
effective in reversing drug resistance in nematodes?
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